Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: A randomized double-blind placebo-controlled trial

Modern Rheumatology

Volumn 22, Issue 3, 2012, Pages 382-393

  Miyasaka, Nobuyuki ^a   Hara, Masako ^b   Koike, Takao ^c   Saito, Eizo ^d   Yamada, Masahito ^e   Tanaka, Yoshiya ^f  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d TOHO UNIVERSITY   (Japan)

^e KANAZAWA UNIVERSITY   (Japan)

^f UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Dermatomyositis (DM); Intravenous immunoglobulin (IVIG); Manual muscle test (MMT); Polymyositis (PM); Randomized, double blind, placebo controlled study

Indexed keywords

CORTICOSTEROID; CREATINE KINASE; GB 0998; GLUCAN; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; PLACEBO; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD PRESSURE; BRONCHITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DERMATOMYOSITIS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; DYSPHAGIA; ENZYME BLOOD LEVEL; ERUCTATION; FATIGUE; FEMALE; GINGIVITIS; GLUCOSE TOLERANCE; HEADACHE; HOT SENSATION; HUMAN; HYPERKALEMIA; IMMUNOTHERAPY; MALE; MOUTH INFECTION; MUSCLE STRENGTH; NAUSEA; POLYMYOSITIS; PRIORITY JOURNAL; PURPURA; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SENSATION; SIDE EFFECT; SWEATING; THORAX PAIN; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ACTIVITIES OF DAILY LIVING; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; CROSS-OVER STUDIES; DERMATOMYOSITIS; DOUBLE-BLIND METHOD; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; MUSCLE WEAKNESS; PLACEBOS; TREATMENT OUTCOME;

EID: 84865377771     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-011-0534-4     Document Type: Article

References (15)

1. Bradley WG. Polymyositis. Br J Hosp Med. 1977;17:351-5. (Pubitemid 8078671)
2. Cherin P. Recognition and management of myositis. Drugs. 1997;54:39-49. (Pubitemid 27300038)
3. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292:344-7.
4. Hara M, Kinoshita M, Saito E, Hashimoto H, Miyasaka N, Yoshida T, et al. Prospective study of high-dose intravenous immunoglobulin for the treatment of steroid-resistant polymyositis and dermatomyositis. Mod Rheumatol. 2003;13:319-25. (Pubitemid 38208387)
5. Saito E, Koike T, Hashimoto H, Miyasaka N, Ikeda Y, Hara M, et al. Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis. Mod Rheumatol. 2008;18:34-44.
6. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993-2000. (Pubitemid 24015043)
7. Roifman CM, Schaffer FM, Wachsmuth SE, Murphy G, Gelfand EW. Reversal of chronic polymyositis following intravenous immune serum globulin therapy. JAMA. 1987;258:513-5. (Pubitemid 17096184)
8. Dalakas MC. Polymyositis, dermatomyositis, and inclusion body myositis. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al., editors. Harrison's principles of internal medicine. 17th ed. New York: McGraw-Hill; 2008. 2696-703.
9. Aberer W, Bagot M, Braathen L, Chimenti S, Diaz-Perez JL, Hegyi V, et al. Guidelines on the use of high-dose intravenous immunoglobulin in dermatology. European dermatology forum. Available at: Http://www.euroderm.org/edf/images/ stories/guide lines/guideline-on-ivig-aktuell-neu-2008.pdf. Cited 9 March 2010.
10. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases/EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol. 2008;15:893-908.
11. Maugars YM, Berthelot JM, Abbas AA, Mussini JM, Nguyen JM, Prost AM. Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol. 1996;14:263-74. (Pubitemid 26290866)
12. Marie I, Hachulla E, Hatron PY, Hellot MF, Levesque H, Devulder B, et al. Polymyositis and dermatomyositis:short term and longterm outcome, and predictive factors of prognosis. J Rheumatol. 2001;28:2230-7. (Pubitemid 32947868)
13. Oh TH, Brumfield KA, Hoskin TL, Stolp KA, Murray JA, Bassford Jr. Dysphagia in inflammatory myopathy:clinical characteristics, treatment strategies, and outcome in 62 patients. Mayo Clin Proc. 2007;82:441-7. (Pubitemid 46543468)
14. Silbert PL, Knezevic WV, Bridge DT. Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology. 1992;42:257-8.
15. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: Risk of precipitating thromboembolic events. Neurology. 1994;44:223-6. (Pubitemid 24070955)